SignalRx Pharmaceuticals Inc., Crystec Ltd., and ADYA Consulting SAGL are pleased toannounce a new collaboration to develop an inhaled dry powder formulation of SF2523 for the treatmentof pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses. SignalRx SF2523 is a novel, small molecule dual PI3K-BRD4
More
